Compared to daily oral pre-exposure prophylaxis (PrEP), lenacapavir reduces the number of new HIV infections by many more; causes slightly fewer serious unwanted effects; and results in little to no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results